Quick Answer
INTENSITY THERAPEUTICS, INC. reported Net Income of -$11.61 million for fiscal year 2025.
INTENSITY THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$11.61M +28.7% |
-$16.27M -54.4% |
-$10.54M -39.0% |
-$7.58M | — |
| Diluted EPS | -$8.56 +70.7% |
-$29.24 -2018.8% |
-$1.38 +37.8% |
-$2.22 | — |
| Total Assets | $14.10M +194.8% |
$4.78M -72.3% |
$17.30M +884.3% |
$1.76M | — |
| Cash and Equivalents | $11.92M +360.3% |
$2.59M -69.7% |
$8.56M +552.1% |
$1.31M | — |
| Stockholders Equity | $11.88M +307.0% |
$2.92M -77.8% |
$13.16M +187.2% |
-$15.10M -73.8% |
-$8.69M |
| R&D Expense | $6.79M -35.4% |
$10.50M +119.3% |
$4.79M -6.7% |
$5.13M | — |
| Operating Income | -$11.97M +27.8% |
-$16.59M -99.4% |
-$8.32M -10.2% |
-$7.55M | — |
| Shares Outstanding | 2.52M +317.3% |
604,915 -95.6% |
13.71M +302.0% |
3.41M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.67M | +24.0% | -5.3% |
| Diluted EPS | September 30, 2025 | -$0.06 | +76.0% | +53.8% |
| Total Assets | September 30, 2025 | $9.59M | +83.9% | +115.7% |
| Cash and Equivalents | September 30, 2025 | $7.07M | +154.0% | +218.9% |
| Stockholders Equity | September 30, 2025 | $7.22M | +159.9% | +230.7% |
| R&D Expense | September 30, 2025 | $1.55M | -27.8% | +0.8% |
| Operating Income | September 30, 2025 | -$2.73M | +23.4% | -1.0% |
| Shares Outstanding | September 30, 2025 | 49.07M | +253.9% | +87.5% |
- INTENSITY THERAPEUTICS, INC. reported Net Income of -$11.61 million for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +28.7% in Net Income compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported Diluted EPS of $8.56 per share (loss) for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +70.7% in Diluted EPS compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported Total Assets of $14.10 million for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +194.8% in Total Assets compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported Cash and Equivalents of $11.92 million for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +360.3% in Cash and Equivalents compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported Stockholders Equity of $11.88 million for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +307.0% in Stockholders Equity compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported R&D Expense of $6.79 million for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed a decrease of -35.4% in R&D Expense compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported Operating Income of -$11.97 million for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +27.8% in Operating Income compared to the prior fiscal year.
- INTENSITY THERAPEUTICS, INC. reported Shares Outstanding of 2.52 million shares for fiscal year 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +317.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: